Rapidly Identifying HCPs Treating AML: The Lab Data Advantage
Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow,...
Unlocking Precision Targeting in Lysosomal Storage Disorders: How Prognos Health Empowers Commercial Teams
Lysosomal Storage Disorders (LSDs) present a unique challenge for pharmaceutical and biotech...
Unveiling New Insights in NSCLC with Large-Scale FISH Panel Data
The landscape of Non-Small Cell Lung Cancer (NSCLC) treatment is constantly evolving, with...
How Emerging Biomarkers in Non-Small Cell Lung Cancer are Driving New and More Innovative Targeted Treatments
Lung cancer is one of the most common tumors and about 228,000 new cases will be diagnosed in the...
How Prognos is Using COVID-19 Data
Written by Jaclyn Fink, Data Quality Assurance Analyst, Prognos Health.
Factor This: Harnessing Lab-Testing Insights to Support Targeted Oncology Therapies in the Market
On World Cancer Day we recognize the countless brave people who have been affected by cancer and...
Lab Results Uncover Insights for Marketers
Read an interesting article by Jason Bhan, M.D., Chief Medical Officer of Prognos, here on on PM360.
What to Consider if Your Drug is a Targeted Therapy for a New Biomarker
A Follow Up to “Biomarker Testing in Non-Small Cell Lung Cancer“ By Melissa Leonhauser, General...
Available Omnichannel HCP Data Sources
Clinical Diagnostic Data for Omnichannel HCP Promotion Marketing: Part Two We’re excited to share...
Biomarker Testing in Non-Small Cell Lung Cancer
By Bill Bowman, Clinical Solutions Architect